Not a good buy right now: the chart is in a clear downtrend (bearish moving-average stack + weakening MACD) with price sitting on/near key support.
No Intellectia trading signals today (AI Stock Picker and SwingMax are both inactive), so there’s no strong tactical edge to justify jumping in immediately.
Pattern-based forward odds shown are negative across 1-day/1-week/1-month horizons, aligning with the bearish technical setup.
With no fresh news/catalysts and weak fundamentals (tiny revenue vs large losses), the risk/reward is unfavorable for an impatient buyer.
Technical Analysis
Trend: Bearish. Moving averages are stacked down (SMA_200 > SMA_20 > SMA_5), indicating sustained downside momentum.
Momentum: MACD histogram is below zero (-0.0156) and negatively expanding, suggesting bearish momentum is strengthening rather than stabilizing.
RSI: RSI(6) at ~26.77 indicates oversold/pressed conditions; this can spark short bounces, but it is not a reliable buy signal while trend/momentum remain bearish.
Key levels: S1 ~1.042 (price is ~1.04, essentially sitting on first support). A clean break risks a move toward S2 ~0.905. Upside resistance levels are Pivot ~1.263 then R1 ~1.485.
Near-term statistical trend (pattern-based): 70% chance of ~-0.57% next day, ~-1.42% next week, ~-5.23% next month—bearish bias.
Pre-market is up (+4.63%) while regular session is down (-2.78%), which can indicate short-term dip-buying interest.
RSI is oversold-ish (short lookback), which sometimes supports a brief technical bounce.
Gross margin reported at ~62.74% (though on very small revenue), which is directionally better than low-margin profiles if revenue ever scales.
Neutral/Negative Catalysts
No news in the recent week: no obvious event-driven catalyst to reverse sentiment.
Financial Performance
Latest quarter provided: 2023/Q4.
Revenue: ~214,761 with 0.00% YoY change (no growth indicated).
Net income: ~-5,183,327 (large loss) with 0.00% YoY change (no improvement indicated).
EPS: ~-0.27 with 0.00% YoY change.
Takeaway: financial profile shows minimal revenue base and substantial ongoing losses; fundamentals do not currently support an aggressive buy-the-dip entry.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so recent Wall Street upgrades/downgrades cannot be confirmed.
Practical read-through from available data: without visible positive analyst revisions/catalysts and with weak fundamentals + bearish technicals, the “pro” case is limited to speculative mean-reversion, while the “con” case (trend + losses + support-risk) dominates.
Political/influential trading: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14 USD with a low forecast of 14 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14 USD with a low forecast of 14 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.990
Low
14
Averages
14
High
14
Current: 0.990
Low
14
Averages
14
High
14
Maxim Group
Michael Okunewitch
Strong Buy
Initiates
$14
AI Analysis
2025-02-14
Reason
Maxim Group
Michael Okunewitch
Price Target
$14
AI Analysis
2025-02-14
Initiates
Strong Buy
Reason
Maxim initiated coverage of Mainz Biomed with a Buy rating and $14 price target.
